drugset / Trial / NCT06515730
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
Phase 4
Recruiting
212 enrolled
Karolinska Institutet
Karolinska Trial Alliance · collabStockholm County Council ALF/PPG · collabSwedish Heart Lung Foundation · collabThe Swedish Research Council · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The optimal anticoagulant for the treatment of left ventricular (LV) thrombus following acute myocardial infarction (AMI) is unclear. The aim of this multicenter randomized study is to evaluate the efficacy of apixaban versus warfarin with respect to thrombus resolution in patients with LV thrombus after AMI.
Timeline
- Start
- 2025-04-08
- Primary completion
- 2028-04-08
- Completion
- 2028-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 2.5 mg | — |
| Subject | Apixaban | Small molecule | 5 mg | — |
| Comparator | Warfarin | Small molecule | 2.5 mg | — |